Advanced search
Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 31, 2024 - Issue 2
Submit an article Journal homepage
113
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis

K. H. Vincent LauAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1416-5589View further author information
ORCID Icon,
Tatiana ProkaevaAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USAView further author information
,
Luke ZhengAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USAView further author information
,
Gheorghe DorosAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USAView further author information
,
Michelle C. KakuAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USAView further author information
,
Brian SpencerAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USAView further author information
,
John BerkAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USAView further author information
&
Vaishali SanchorawalaAmyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0002-6307-2445View further author information
ORCID Icon show all
Pages 150-152 | Received 29 Aug 2023, Accepted 26 Nov 2023, Published online: 11 Dec 2023

References

  • Zampino S, Sheikh FH, Vaishnav J, et al. Phenotypes associated with the Val122Ile, Leu58His, and late-onset Val30Met variants in patients with hereditary transthyretin amyloidosis. Neurology. 2023;100(19):e2036–e2044. doi: 10.1212/WNL.0000000000207158.
  • Luigetti M, Guglielmino V, Romozzi M, et al. Nerve conduction studies of dorsal sural nerve: normative data and its potential application in ATTRv pre-symptomatic subjects. Brain Sci. 2022;12(8):1037.
  • Louwsma J, Brunger AF, Bijzet J, et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid. 2021;28(1):50–55. doi: 10.1080/13506129.2020.1815696.
  • Maia LF, Maceski A, Conceição I, et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid. 2020;27(2):97–102. doi: 10.1080/13506129.2019.1708716.
  • Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology. 2021;96(3):e412–e422. doi: 10.1212/WNL.0000000000011090.
  • Romano A, Primiano G, Antonini G, et al. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis? Eur J Neurol. 2023. doi: 10.1111/ene.16070.
  • Ticau S, Aldinc E, Polydefkis M, et al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid. 2023;1–11. doi: 10.1080/13506129.2023.2232520.
  • Sato M, Mochizuki Y, Takahashi Y, et al. Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis. Amyloid. 2023;30(3):351–352. doi: 10.1080/13506129.2023.2187678.
  • Loser V, Benkert P, Vicino A, et al. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis—a Swiss Reference Center experience. J Peripher Nerv Syst. 2023;28(1):86–97. doi: 10.1111/jns.12524.
  • Fitzgerald KC, Sotirchos ES, Smith MD, et al. Contributors to serum NfL levels in people without neurologic disease. Ann Neurol. 2022;92(4):688–698. doi: 10.1002/ana.26446.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.